



**For Immediate Release**

**April 4, 2022**

## **Abi Coman-Walker Named Chief Operating Officer at Acuitas Therapeutics**

**Vancouver, B.C.** – Abi Coman-Walker has been promoted to Chief Operating Officer (COO) at Acuitas Therapeutics, Dr. Thomas Madden, Acuitas President & CEO announced recently. Ms. Coman-Walker was the Senior Director of Finance & Operations at the private biotech firm.

Prior to joining Acuitas in early 2021, Ms. Coman-Walker worked at HSBC, where she held senior roles in seven countries including: Strategic Programme Director; Chief Operating Officer, Wealth and Personal Banking; and Global Head of Business Financial Crime and Regulatory Risk, Retail Banking & Wealth Management.

“Abi is instrumental in effectively planning and managing the exceptional growth of the organization, while maintaining our positive, supportive and collaborative culture,” said Dr. Madden. He added: “Her strategic insight, focus on operational excellence, and in-depth knowledge in operations and finance are key assets for Acuitas. Abi has taken on a true leadership role in taking our commitment to equity, diversity and inclusion forward. From the moment she joined us, Abi has proven herself as an authentic team player – someone who leads by lifting others up. We are delighted that she has stepped into the role of COO.”

### **About Acuitas Therapeutics**

Founded in February 2009, Vancouver-based Acuitas Therapeutics ([www.acuitastx.com](http://www.acuitastx.com)) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY<sup>®</sup>, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries.

-END-